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Abstract
Biallelic mutations in MCPH1 cause primary microcephaly (MCPH) with the cellular phenotype of defective chromosome
condensation. MCPH1 encodes a multifunctional protein that notably is involved in brain development, regulation of
chromosome condensation, and DNA damage response. In the present studies, we detected that MCPH1 encodes several
distinct transcripts, including two major forms: full-length MCPH1 (MCPH1-FL) and a second transcript lacking the six 39
exons (MCPH1De9–14). Both variants show comparable tissue-specific expression patterns, demonstrate nuclear localization
that is mediated independently via separate NLS motifs, and are more abundant in certain fetal than adult organs. In
addition, the expression of either isoform complements the chromosome condensation defect found in genetically MCPH1-
deficient or MCPH1 siRNA-depleted cells, demonstrating a redundancy of both MCPH1 isoforms for the regulation of
chromosome condensation. Strikingly however, both transcripts are regulated antagonistically during cell-cycle progression
and there are functional differences between the isoforms with regard to the DNA damage response; MCPH1-FL localizes to
phosphorylated H2AX repair foci following ionizing irradiation, while MCPH1De9–14 was evenly distributed in the nucleus.
In summary, our results demonstrate here that MCPH1 encodes different isoforms that are differentially regulated at the
transcript level and have different functions at the protein level.
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Introduction
Primary autosomal recessive microcephaly (MCPH, OMIM
606858) is a non-syndromic neurodevelopmental disorder in which
the cerebral cortex volume is significantly reduced. The head
circumference of MCPH patients is at least three standard deviations
below that of unaffected individuals of the same age and sex [1].
MCPH patients exhibit grossly normal brain architecture: however,
they also exhibit simplified gyral patterns [2]. Affected individuals
are mentally retarded but lack significant neurological deficits.
At least eight different loci (MCPH1 –MCPH8) are associated with
MCPH [3–10]. Seven of the underlying genes with their products
have been identified and characterized to date: MCPH1/micro-
cephalin, MCPH2/WDR62, MCPH3/CDK5RAP2, MCPH4/-
CEP152, MCPH5/ASPM, MCPH6/CENP, and MCPH7/STIL
[11–16]. The human MCPH1 gene is located on chromosome
8p23.1, is organized into 14 exons and encodes a protein composed
of 835 amino acids (fig. 1a).
Biallelic mutations in the MCPH1 gene are associated with a
distinctive cellular phenotype which consists of excess (10–20%)
prophase-like cells (PLCs) among metaphase spreads. PLCs result
from premature chromosome condensation (PCC) in the G2 phase
of the cell cycle and delayed decondensation in the post-mitotic G1
phase (PCC syndrome, OMIM 60858) [17,18]. Previous research
has shown that MCPH1 acts as a negative regulator of condensin
II which prevents PCC until the onset of prophase and allows
timely chromosome decondensation after mitosis [19,20]. An
additional explanation for PCC involves the low levels of
phosphorylated CDK1 at tyrosine residue 15 observed in
MCPH1-mutant cells [21].
MCPH1 is predicted to contain a single N-terminal and tandem
C-terminal BRCA1 carboxyl terminal (BRCT) domains in
addition to a canonical nuclear localization signal (NLS) sequence
[11]. BRCT domains are present in numerous proteins involved in
cell cycle checkpoint functions (e.g., NFBD1/MDC1 and 53BP1)
[22]. Because phosphoprotein binding domains of BRCT type are
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responsive to DNA damage [23], various studies have attempted
to clarify the role of MCPH1 in DNA repair pathways. It has been
shown that MCPH1 is recruited to lesions induced by a variety of
DNA damaging agents [24]. MCPH1 is required for the formation
of ionizing radiation (IR)-induced nuclear foci involving NBN,
53BP1, MDC1 and ATM and for ultraviolet light-induced foci
such as ATR, RPA34, and RAD17 [25]. The C-terminal BRCT
domains of MCPH1 appear to be crucial for nuclear foci
formation [24]. According to studies using siRNA, downregulation
of MCPH1 impairs the IR-induced intra-S-phase and G2/M
checkpoints [25]. In addition, downregulation of MCPH1
expression decreases the transcript and protein levels of BRCA1
and CHK1 [26,27]. These studies suggest that MCPH1 functions
in an ATM- and ATR-dependent manner but upstream of both
the ATM- and the ATR-signaling pathways. Generally, the
impairment of mechanisms that regulate the function of DNA
damage-induced cell cycle checkpoints and other DNA damage
responses results in genomic instability and a predisposition to
malignancies. In view of these findings, it is remarkable that
patients whose cells have truncating mutations in MCPH1 show
normal expression levels of CHK1 and BRCA1 [21] and display a
proficient G2/M checkpoint following ionizing irradiation [28].
Interestingly, none of the patients with biallelic mutations in
MCPH1 have been reported to have cancer [11,17,29,30]. On the
other hand, Mcph1-deficient mice have been shown to have a
reduced lifespan: however, the reasons for premature death of
these animals remain elusive [31]. Moreover, Liang et al. [32]
observed that Mcph1 is essential for DNA repair and the
maintenance of genomic stability in mice.
The multitude of functions claimed to MCPH1 could perhaps
be explained by existence of different isoforms with different
functions. Alternative splicing of the MCPH1 gene has been
observed in Drosophila [33]. In this report we investigated the
expression of different transcript forms of the humanMCPH1 gene
and characterized MCPH1 isoforms by comparing MCPH1-
deficient cells and their stably complemented counterparts.
Results
Alternative transcripts of human MCPH1
We first screened the databases for the existence of alternatively
spliced MCPH1 transcripts. In addition to full-length MCPH1
(MCPH1-FL), the Alternative Splicing and Transcript Diversity
Figure 1. The human MCPH1 gene, its transcripts and predicted polypeptides. (A) Exon (filled boxes) and intron (open boxes) organization
of the 241 906-bp encompassing MCPH1 gene locus. Red arrows indicate the positions of the regular and of the alternative (*) polyadenylation sites
(polyA). (B) The full-length (FL) and the alternative transcripts De9–14, De1–3, and De8: numbered boxes indicate exons, black filled areas illustrate
the entire coding regions (CDS), and colored areas show untranslated regions (UTR) as indicated. (C) Predicted polypeptides representing MCPH1
isoforms: blue boxes depict the positions of BRCT domains, while green boxes represent the site of the canonical nuclear localization signal sequence
(NLS). Two additional amino acids, S and M, are included into MCPH1De9–14 prior to premature termination (#). (D) Expression of MCPH1 transcript
variants. Columns represent the levels of MCPH1 transcripts in indicated adult and fetal tissues determined using quantitative real-time PCR. Data
represent means 6 one S.D. of three independent experiments and are normalized to the geometric mean levels of UBC, GAPDH, B2M, and HPRT1
cDNA.
doi:10.1371/journal.pone.0040387.g001
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database (ASTD) [34] includes a variant lacking the first three
exons (MCPH1De1–3) and another lacking exons 9–14
(MCPH1De9–14) (fig. 1b). The latter is also registered as clone
BC030702.1 in the GenBank database and arises from premature
polyadenylation within intron 8, probably due to an alternative
polyadenylation site in that intron. Indeed, a database for
polyadenylation sites in vertebrate genes (polyA_DB.2) [35]
includes a cluster of polyadenylation sites in intron 8 of human
MCPH1 (polyA* in fig. 1a). This premature polyadenylation results
in exonization of 1 025 nt of the 59 portion of intron 8, creating a
new stop codon two codons downstream of the original exon 8 and
an alternative 39 UTR. The corresponding protein has a predicted
size of approximately 70 kDa and lacks the two C-terminal BRCT
domains (fig. 1c). The expression of this variant was verified by
RT-PCR using a forward primer complementary to the 59 end of
MCPH1 CDS and a reverse primer located within intron 8.
The other variant, MCPH1De1–3 has previously been de-
scribed in a general genetic screen for negative regulators of
hTERT [36]. However, this variant was first described as full-
length MCPH1 and not as an alternative transcript. It would
encode MCPH1 lacking the N-terminal BRCT domain. The
existence of MCPH1De1–3 could be explained by the use of
alternative transcriptional start sites (TSSs) in exon 4. To test this
hypothesis, we performed 59 RACE using RNA isolated from
HeLa and 293T cells. Subcloning of the 59 RACE products and
subsequent sequencing of several clones revealed a cluster of TSSs,
which were all located within exon 1. This finding is in agreement
with the positions of TSSs annotated in the ASTD databank
indicating that MCPH1De1–3 is not physiologically expressed:
therefore, this variant was omitted from further experiments.
In contrast, we found a novel splicing variant of the human
MCPH1 gene using RT-PCR with primers complementary to the
extreme ends of the coding region of full-length MCPH1. Two
prominent bands with sizes of 2 500 bp and 1 300 bp were
detected using agarose gel electrophoresis. Sequencing revealed
that the 2 500-bp band corresponded to MCPH1-FL, while the
1 300-bp product resulted from an MCPH1 alternative transcript
that completely lacked exon 8 (MCPH1De8, fig. 1b). The
exclusion of exon 8 causes in-frame skipping of 1 155 bp and
results in a theoretical protein of 450 amino acids, with a predicted
molecular weight of approximately 50 kDa. The deduced
polypeptide contains all three BRCT domains but lacks the
putative NLS motif, which is encoded by exon 8. The skipping of
exon 8 in MCPH1De8 and the exonization of intron 8 in
MCPH1De9–14 are probably due to a weak 59 splice site in intron
8. Indeed, analyzing the 59 splice sites of MCPH1 introns using the
splice site prediction algorithm NNSPLICE [37] revealed a score
of 0.69 for the 59 splice site of intron 8 while all the others ranged
between 0.94 and 1 (table S1).
Expression pattern of alternative human MCPH1
transcripts
Recovering of an alternative transcript is not equivalent with
physiological functionality of this variant. The expression level can
give a clue to the relevance of an alternative transcript. Therefore,
we examined whetherMCPH1 transcripts are differently expressed
in certain tissues. Quantitative real-time PCR of human fetal and
adult tissues revealed that the mRNA levels of MCPH1-FL and
MCPH1De9–14 were similarly abundant in all tissues tested
(fig. 1d and table S2). Some tissues exhibited increased expression
of both isoforms in the fetal stage compared with the respective
adult samples (such as brain, heart, and thymus). Notably, the
expression of both isoforms indicated significant differences
between fetal and adult brain samples. Specifically,
MCPH1De9–14 was overexpressed approximately five fold in
the fetal brain compared with the adult brain. This observation is
consistent with the role of MCPH1 in the development of the
cerebral cortex. In contrast, MCPH1De8 was detected at low
levels, comparable to background noise, indicating that this
isoform is probably a byproduct of splicing events.
Cell cycle-dependent transcription of MCPH1 isoforms
Because MCPH1 is involved in cell cycle regulation, we sought
to determine if expression of MCPH1 transcript forms was subject
to cell cycle-dependent control. HeLa cells were synchronized
using a double thymidine block. Cell synchrony was monitored
using flow cytometry of DAPI-stained cells, and total RNA was
isolated at various time points as depicted in fig. 2. Quantitative
PCR demonstrated that the amount of MCPH1-FL mRNA
decreased from mid-S phase to G2 phase. In contrast, the
transcript levels of MCPH1De9–14 were downregulated during
early S phase but increased during late S and G2. The combined
level of MCPH1-FL and De9–14 transcripts did not vary
significantly. Because MCPH1-FL and De9–14 contain the same
59 region, the transcription of both isoforms should be regulated by
the same promoter. Thus, we suppose that up- and downregula-
tion of each variant might occur at posttranscriptional stages.
MCPH1De8 transcripts were detectable at low levels at all-time
points, supporting again the idea that this variant is a byproduct of
splicing events. Transcript levels of the reference genes GAPDH
and B2M were identical in all samples, indicating the validity of
the observed variation in MCPH1 expression regardless of RNA
input or synchronization procedure.
Ectopic expression of MCPH1 isoforms
Transient expression of MCPH1 has been reported in several
studies, but none of these studies used stable cell lines with
ectopically expressed MCPH1. Our preliminary experiments
showed that unregulated overexpression of MCPH1 causes cell
death. Therefore, we expressed the three MCPH1 isoforms by
cloning the respective cDNA into a lentiviral vector containing a tet
operator (tetO) sequence followed by co-transduction of this vector
with another vector that expressed a transcriptional repressor, the
tetracycline-controlled hybrid protein tTR-KRAB [38]. Using
these constructs, we obtained stable cell lines that exhibited
conditional doxycycline-dependent expression of N-terminal GFP-
tagged MCPH1 in transformed fibroblasts (562T) derived from a
patient with the homozygous nonsense mutation c.427dupA
(p.N143fsX147) in MCPH1. Western blot analysis revealed that
increasing doxycycline concentrations resulted in increased GFP-
MCPH1 expression (fig. 3a–b). For further experiments, we used
1 ng/ml doxycycline to induce the expression of GFP-MCPH1
fusion proteins. We checked the expression of the GFP-MCPH1
fusion proteins using immunoblotting. As shown in fig. 3c,
monoclonal antibodies against GFP detected bands of the
appropriate size, which were not present in samples from non-
transduced cells or cells transduced only with the tTR-KRAB
vector. Similar results were obtained using commercially available
antibodies against MCPH1. While the commercial antibody
AF3998 detected all three isoforms, another such antibody,
ab2612, failed to detect MCPH1De8 because it lacks the antigenic
epitope located within the inter-BRCT region (data not shown).
Complementation of the PCC phenotype in MCPH1-
deficient cells
To analyze the ability of MCPH1 isoforms to complement the
defective chromosome condensation in MCPH1-deficient 562T
Analysis of MCPH1 Isoforms
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cells, chromosome spreads were prepared from 562T cells
expressing the GFP-MCPH1 isoforms, and the proportion of
prophase-like cells (PLCs) was determined (fig. 4). Interestingly, all
three isoforms were able to complement the PCC phenotype
(fig. 4c–e). While the proportion of PLCs in non-transduced cells
(16%) or in cells expressing GFP alone (21%) was typical for PCC
syndrome, cells expressing MCPH1-FL, De9–14, or De8 exhibited
a reduced number of PLCs (0.3%–1.3%) in the normal range.
Figure 2. Cell cycle-dependent regulation of MCPH1 transcripts. (A) HeLa cells were arrested in G1 phase by double thymidine block.
Cultures harvested at various time points after release were analyzed using flow cytometry. (B) Plots represent numbers of cells as a function of their
DNA content. A total of 90% of the cells synchronously progressed into S phase (0–4 h), entered G2 phase (4–6 h), started passing through mitosis
after 7 h, and were completely in G1 phase after 12 h. (C) Levels of MCPH1-FL (diamonds, solid line), MCPH1De9–14 (squares, dotted line), and
MCPH1De8 (circles, dashed line) mRNA. Data represent means 6 S.E.M. of three independent experiments and are normalized to the expression
levels of GAPDH and B2M.
doi:10.1371/journal.pone.0040387.g002
Figure 3. Expression of GFP-tagged MCPH1 isoforms in MCPH1-deficient 562T fibroblasts. (A) Cells were transduced with GFP-tagged
coding sequence of full-length MCPH1 cDNA in a conditional, doxycycline (DOX)-dependent construct with a second regulatory construct trKRAB.
Cultures were exposed to increasing DOX concentrations as indicated. Whole-cell extracts were prepared 72 h later and analyzed for the expression
of MCPH1 using immunoblotting with an antibody against GFP. (B) The graph shows MCPH1 band intensity relative to the loading control p84
plotted against DOX concentrations. Data represent means 6 one S.D. of three independent assays. (C) Immunoblot analysis of whole-cell extracts
from non-transduced (NT) 562T cells (lane 1), 562T cells transduced with the regulatory construct only (lane 2), with GFP alone (30 kDa, lane 3) or with
GFP fused to MCPH1-FL (120 kDa, lane 4), MCPH1De9–14 (94 kDa, lane 5), MCPH1De8 (78 kDa, lane 6), or MCPH1De1–7 (96 kDa, lane 7) with an
antibody against GFP.. Nuclear matrix protein p84 served as the loading control.
doi:10.1371/journal.pone.0040387.g003
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Mitotic indices were similar in all samples (5%60.8%, fig. 4g),
confirming that the reduction in the proportion of PLCs was not
due to reduced proliferative activity.
Comparing the protein sequences of the various MCPH1
isoforms revealed that the N-terminal BRCT domain was
common to all three variants (fig. 1c). For this reason and
considering that all of the mutations described in MCPH1 patients
are located within the first seven exons, we created a deletion
construct lacking exons 1–7 (MCPH1De1–7) and subcloned it into
the same vector described above. This particular construct,
predicted to encode an MCPH1 isoform with a deleted N-
terminal BRCT domain failed to complement the PCC pheno-
type, showing the same proportion of PLCs (17%, fig. 4f) as non-
transduced 562T cells, confirming the importance of this region of
MCPH1 for the proper condensation of chromosomes.
Only simultaneous downregulation of MCPH1-FL and
De9–14 cause the cellular phenotype of PCC
Trimborn et al. [18] have previously shown that the downreg-
ulation of MCPH1 using RNAi causes the cellular phenotype of
misregulated chromosome condensation in HeLa cells. The
siRNA sequence used by Trimborn et al. was directed against
exon 8 of the MCPH1 gene, making it able to deplete both FL and
De9–14 transcripts. In an extension of these previous studies, we
investigated whether the downregulation of each variant individ-
ually would affect chromosome condensation. Transcript De8 was
omitted from this experiment because of its marginal expression
levels. Because MCPH1-FL and De9–14 contain different 39 UTR
sequences (fig. 1b), siRNA specific to these sequences allowed us to
downregulate each variant individually. HeLa cells were trans-
fected with siRNA duplexes specific for exon 8 of MCPH1 to
deplete the both transcripts, or to the 39 UTRs of FL or De9–14 to
deplete them separately. Downregulation of MCPH1 was mon-
itored using immunoblotting with an MCPH1-specific antibody
(fig. 5a). Discrete bands at approximately 100 kDa and 75 kDa
were detected, which correspond to MCPH1-FL and De9–14, and
disappeared when the cells were treated with siRNA specific to the
39 UTR of FL or De9–14, respectively. As expected, the siRNA
against exon 8 of MCPH1 or the combination of isoform specific
siRNAs led to the downregulation of both variants.
Figure 4. Complementation of PCC in patient fibroblasts. Cells are derived from patient with homozygous truncating mutation c.427dupA
(p.T143NfsX5) in MCPH1. Chromosome preparations from (A) non-transduced cells and (B) cells expressing GFP only, or GFP fusions with (C) full-
length, (D) De9–14, (E) De8, or (F) De1–7 MCPH1. Arrows indicate nuclei of prophase-like cells (PLCs). (G) Mean rates of PLCs (filled columns) of slides
from A-F. Open columns represent mean mitotic indices. Error bars denote the S.D. of counts of approximately 1000 cells each from three
independent experiments.
doi:10.1371/journal.pone.0040387.g004
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As shown in fig. 5b, individual downregulation of each of the
variants failed to affect the regulation of chromosome condensa-
tion. Only the combined depletion of both variants induced the
PCC cellular phenotype. This observation is fully consistent with
the results of the complementation assays described above, which
show that both isoforms are redundant regarding the regulation of
chromosome condensation.
Intracellular localization of MCPH1 isoforms
Centrosomal localization has been described for human
MCPH1 in U2OS cells and for chicken cMCPH1 in DT40 cells
[39,40]. We examined the centrosomal localization of MCPH1
isoforms in 562T and HeLa cells, both expressing GFP-MCPH1,
using antibodies against the centrosomal proteins c-tubulin and
pericentrin. Surprisingly, there was no evidence for the centroso-
mal localization of any of the ectopically expressed MCPH1
isoforms (fig. S1 and S2).
To gain insight into the subcellular localization of the MCPH1
isoforms, 562T fibroblasts transduced with GFP fusion constructs
were fractionated, and proteins extracted from the nuclear and
cytoplasmic fractions were analyzed using immunoblotting (fig. 6a).
The purity of each fraction was confirmed using antibodies against
the nuclear matrix protein p84 and GAPDH, respectively.
Expression of GFP alone demonstrated the expected distribution
in both the cytoplasm and the nucleus. In contrast, all GFP-tagged
MCPH1 variants were predominantly located in the nucleus-
derived cell fraction. Although low levels of MCPH1De8 were
detected in the cytoplasm, a more intense signal even from this
isoform was seen in the nucleus despite the predicted absence of
the canonical NLS. Importantly, the mutant variant MCPH1De1–
7 could be localized in nucleus as well demonstrating that the
failure of this particular variant to complement the PCC
phenotype is not due to defective nuclear targeting. As shown in
fig. 6b, these results were confirmed using fluorescence microscopy
of DAPI-stained cells.
NLS analysis of MCPH1
To explain the nuclear targeting of MCPH1De8, we employed
an in silico screen of the MCPH1 protein for NLS motifs using the
PSORT II prediction program [41]. In addition to the canonical
bipartite NLS encoded by the exon 8 motif
KRKRVSHGSHSPPKEKCKRKR, we identified two further
motifs with predicted NLS functions (KKKRK, localized at the N-
terminus, and PYSGKKK, localized at the C-terminus; fig. 7a).
We designated these three putative nuclear localization signals
NLS1, NLS2 and NLS3. Using PCR-based in vitro mutagenesis,
variants with different combinations of deleted NLS motifs in
GFP-MCPH1 fusion constructs were generated for transfection
into HeLa cells. GFP expressed from a control pEGFP-N3 vector
was distributed evenly between the cytoplasm and the nucleus,
whereas GFP fused to wild-type (wt) MCPH1 was detected almost
exclusively (78%64%) within the nuclear fraction (fig. 7b–c).
Deletion of NLS1 or NLS2 alone had no effect on nuclear
localization, whereas MCPH1 with a deleted NLS3 shifted slightly
but statistically significant (p,0.05, t-test versus wt MCPH1) the
GFP distribution to the cytoplasmic fraction. Pairwise deletions of
NLS1 with NLS2 or NLS3 did not change noticeably the
localization of mutated isoforms, however, in comparison to wt
MCPH1 the effect was significant (p,0.05, t-test). Finally, the
absence of NLS2 and NLS3 or of all three NLS motifs consistently
affected the nuclear localization of MCPH1 (44% of the GFP
signal within the nucleus; p,0.05 versus wt MCPH1). The purity
of each fraction was controlled using antibodies against the nuclear
matrix protein p84 and GAPDH. Similar results were obtained
using transiently transfected COS-7 and 293T cells (data not
shown).
Formation of repair foci by MCPH1 isoforms
Using fluorescence microscopy of 562T fibroblasts ectopically
expressing the GFP-fused MCPH1 isoforms, we observed
MCPH1-FL and MCPH1De8 in punctuate nuclear speckles in
10.8% and 4.8% of cells, respectively, whereas MCPH1De9–14
was evenly distributed in the nucleus. In addition, the mutant
isoform De1–7 also formed foci (in 5.8% of cells), indicating the
requirement of C-terminal BRCT-domains for foci formation
(data not shown).
Because it is known that MCPH1 relocates to sites of DNA
damage [24,27], we examined which of the MCPH1 isoforms was
involved in IR-induced foci formation. In this experiment, we
irradiated 562T cells ectopically expressing the GFP-fused
MCPH1 isoforms with 10 Gy and analyzed the formation of
MCPH1 and cH2AX foci two hours later. As expected, MCPH1
foci were formed by MCPH1-FL, De8 or De1–7 but not the
isoform De9–14, which lacks the C-terminal BRCT tandem
(fig. 8a). Interestingly, in cell lines expressing De8 or De1–7, fewer
cells (13.7% and 11.7%) showed MCPH1 foci formation
compared with lines expressing MCPH1-FL (28%).
Figure 5. Only simultaneous downregulation of endogenous full-length (FL) and De9–14 MCPH1 induces PCC. (A) Immunoblots with
an anti-MCPH1 antibody after transfection of HeLa cells with different siRNAs demonstrate efficient downregulation of either MCPH1-FL (93 kDa) or
MCPH1De9–14 (70 kDa) or both isoforms (exon 8 and FL+ De9–14) but no downregulation in response to non-targeting siRNA or mock-transfected
controls. Nuclear matrix protein p84 served as a loading control. (B) Columns represent PLC rates in HeLa cells transfected with MCPH1 siRNA as
indicated in A. Error bars denote the S.D.
doi:10.1371/journal.pone.0040387.g005
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In contrast, cH2AX foci were detected in all samples, indicating
that the formation of cH2AX foci is independent of MCPH1
expression or MCPH1 foci formation (fig. 8b–c). Interestingly,
however, in cell lines ectopically expressing MCPH1-FL, De9–14
or De8, we observed elevated cH2AX foci formation (49%, 60%
and 62% of the total cell population, respectively) when compared
with cells expressing only GFP or the De1–7 variant (40.6% and
37.5% of the total cell population, respectively).
Discussion
The MCPH1 gene is mutated in patients with primary
microcephaly and misregulated chromosome condensation. The
existence of BRCT domains in MCPH1 and studies using RNAi
against MCPH1 suggest a role for MCPH1 in cell-cycle
checkpoint control and in the DNA damage response
[21,24,42]. These previous studies assumed that there was a
single MCPH1 isoform. However, the multitude of functions
attributed to MCPH1 suggests the existence of multiple MCPH1
isoforms. Alternative splicing of pre-mRNA allows the formation
of multiple transcripts from a single gene, contributes to proteome
diversity, and provides a level of gene regulation [43]. Of note,
46% of alternatively spliced genes are involved in signal
transduction or gene expression regulation [44]. In addition,
alternative transcription initiation and alternative choices of
polyadenylation sites further enhance proteome diversity [45].
Here we provide evidence for two additional isoforms of
MCPH1 produced by alternative splicing and alternative polyad-
enylation. One of these novel isoforms, MCPH1De9–14, was
found to be as abundant as the full-length transcript in several
Figure 6. Intracellular distribution of MCPH1 isoforms. (A) MCPH1-deficient fibroblasts expressing GFP alone or the specified GFP-MCPH1
fusion proteins were fractionated and cytoplasmic (Cyt) and nuclear (Nuc) protein extracts were analyzed using immunoblotting with an antibody
against GFP. The nuclear matrix protein p84 and GAPDH were used as index proteins and loading controls. (B) Cells indicated in A stained with an
anti-GFP antibody (green), counterstained with DAPI (blue) and analyzed using fluorescence microscopy. Arrows indicate the prophase-like nuclei.
Scale bar = 10 mm. All MCPH1 isoforms exhibit unambiguous nuclear localization.
doi:10.1371/journal.pone.0040387.g006
Figure 7. Nuclear localization signals (NLSs) in human MCPH1. (A) The positions of the putative NLS motifs and their amino acid sequences
are highlighted in the diagram of the full-length MCPH1. (B) Subcellular distribution of GFP-tagged wild-type (wt) MCPH1 and mutants with deleted
NLSs as indicated were transiently expressed in HeLa cells. Cytoplasmic (Cyt) and nuclear (Nuc) protein extracts were immunoblotted with an
antibody against GFP (left panel). GAPDH (center panel) and the nuclear matrix protein p84 (right panel) served as index proteins and loading
controls. (C) Ratios of relative GFP band intensity in the cytoplasmic (Cyt) vs. nuclear (Nuc) fractions. Absolute numbers were assessed using
densitometry and normalized to the loading controls. Columns designate means, and error bars represent the S.D. from three different experiments.
Significant differences to wt MCPH1 are indicated by asterisks denoting p,0.05 (Student’s t-test). Scale bar = 10 mm.
doi:10.1371/journal.pone.0040387.g007
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adult and fetal tissues, suggesting the functionality of this particular
isoform. In contrast, the low copy number detected for
MCPH1De8 argues against relevance of this variant. However,
we found that both novel isoforms were able to complement the
defective chromosome condensation in cells derived from MCPH1
patients. Apparently, the N-terminal BRCT domain of MCPH1 is
sufficient to rescue the PCC phenotype in MCPH1-deficient cells.
This finding is consistent with results obtained from studies of
MCPH12/2 mouse embryonic fibroblasts (MEFs), which also
recapitulate the defective chromosome condensation observed in
human MCPH1-deficient cells [46]. Similar to our results, the
PCC defect in MCPH12/2 MEFs could be rescued by wt
MCPH1 or variants containing the N-terminal BRCT domain. In
a recent study the X-ray crystal structure of this domain was
elucidated [47]. The N-terminal BRCT domain of MCPH1
contains a hydrophobic pocket in the equivalent structural position
to the phosphate binding site found in other BRCT domains.
Mutations in this pocket abrogate the ability of full length Mcph1
to rescue the PCC phenotype in MCPH12/2 MEFs. Moreover,
Yamashita et al. [20] investigated the specific role of hMCPH1 in
regulation of chromosome condensation using Xenopus egg
extracts. They found that hMCPH1 inhibits loading of condensing
II by competing for its binding sites on chromosomes and that the
N-terminal domain of hMCPH1 is required and sufficient for this
inhibitory activity. These data additionally support our findings on
the importance of the N-terminal BRCT domain for the timely
condensation and decondensation of chromosomes.
In contrast to previous reports with U2OS cells [39,48], we
were unable to confirm a centrosomal localization for any of our
GFP- or FLAG-tagged MCPH1 isoforms in HeLa cells or SV40-
transformed 562T fibroblasts. This discrepancy may be due to
tissue or cell-type specificity. In addition to cell line differences,
there is the possibility of uncharacterized isoforms, which could
interact with centrosomes. However, it is important to note that
the Drosophila melanogaster homolog of MCPH1 expresses two
alternatively spliced isoforms mcph1(L) and mcph1(S) [49], which
correspond to human MCPH1-FL and MCPH1De9–14. A
centrosomal localization for mcph1(S) was suggested but could
not be confirmed in the Drosophila studies [33,49]. In contrast,
nuclear localization was observed for both Drosophila variants,
which is fully consistent with our findings on the subcellular
distribution of the human MCPH1 isoforms. While we were
preparing our manuscript, the causative gene located in the
MCPH2 locus was identified. Interestingly, similar contradictory
results are reported concerning the localization ofMCPH2 product
WDR62: while two studies detected WDR62 localization at
mitotic spindles [12,50] another group could not confirm the
centrosomal localization of this protein [51].
The unambiguous nuclear localization of all tested human
MCPH1 isoforms is fully in line with the role of MCPH1 in DNA
damage response and with the presence of multiple NLS motifs
sufficient for targeting these isoforms to the nucleus. Multiple
karyophilic signals with independent activity are common among
nuclear proteins [52,53], maintaining nuclear transport in the
event of point mutations in one of the NLSs. In addition, a
multitude of NLSs may increase the rate of protein-transporter
interaction, whereby transport through the nuclear pores occurs
more effectively [54]. The location of NLS3 within the third
BRCT domain of MCPH1 is consistent with other features
common to nuclear proteins because NLS motifs are frequently
localized in close proximity to DNA-binding or protein-interaction
domains [55]. While the N-terminal domain of MCPH1 seems to
be indispensable for the rescue of defective chromosome
condensation in MCPH1-deficient cells the C-terminal BRCT
tandem appears essential for the localization of MCPH1 to sites of
DNA damage. Our data confirm previous findings which
demonstrated that the ability of MCPH1 to localize to the sites
of DNA double-strand breaks (DSBs) depends on its C-terminal
Figure 8. Colocalization of MCPH1 and cH2AX in ionizing irradiation-induced nuclear foci. (A) Non-transduced (NT) MCPH1-deficient
562T cells and 562T stably expressing GFP alone or the specified GFP-MCPH1 fusion proteins were fixed 2 h after irradiation with 10 Gy and co-
stained with antibodies against cH2AX (red) and GFP (green). Nuclei were counterstained with DAPI (blue). Rectangles frame areas, which are shown
enlarged in the bottom row. MCPH1 focus formation was observed for MCPH1 isoforms containing the C-terminal BRCT tandem. (B) Quantification of
cells expressing foci containing cH2AX and/or (C) MCPH1. Error bars indicate the S.D. of three different measurements, counting approximately 300
nuclei. * p#0.05 vs. NT as calculated using the Student’s t-test.
doi:10.1371/journal.pone.0040387.g008
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tandem BRCT domain [24,40]. Using ITC assay, Wood et al.
[24] also reported that MCPH1 tandem BRCT domains bind
tightly to a phospho-H2AX peptide in vitro. However, our data also
suggest that the inter-BRCT region and the N-terminal BRCT
domain ensure further the MCPH1 foci formation in response to
IR-induced DNA lesions. It is conceivable that MCPH1-FL is
targeted (via its C-terminal BRCT tandem) to the sites of DNA
damage, while De9–14 is responsible for proper condensation and
decondensation of chromosomes during the cell cycle. This
suggestion would mean that the two MCPH1 isoforms have
distinctive functions. However, only simultaneous downregulation
of both isoforms consistently induced the PCC cellular phenotype.
Obviously, the two isoforms can complement each other in some
functions (e.g., chromosomal condensation) but not in others (e.g.,
response to DNA damage).
One paradigmatic case resembling MCPH1 is the human
promyelocytic leukemia protein (PML), which exists in multiple
isoforms generated by alternative splicing that differ in their C-
terminal regions. While isoform PML-III interacts with the
centrosome, the others are localized in the nucleus and serve
different functions [56]. Similar to MCPH1, PML is involved in
multiple cellular activities, such as the DNA damage response,
apoptosis and chromatin modification. Furthermore, a recent
study showed that loss of Pml in mice resulted in decreased cortical
thickness and brain size [57]. Therefore, it remains to be seen
whether additional isoforms of MCPH1 with additional functions
may exist in human cells.
The alternative transcript MCPH1De9–14 exhibits a different
39 UTR, enabling a putative differential regulation of expression
by means of microRNAs (miRNAs). This notion is supported by
the finding that expression of MCPH1-FL and De9–14 alternate in
a cell cycle-dependent manner and independently of each other.
An algorithm for the detection of miRNA binding sites (Micro-
Inspector) revealed binding sites for 97 different miRNAs in the 39
UTR of MCPH1-FL and 52 in the De9–14 transcript, with only
11 miRNAs common to both variants. It has been shown that the
binding of miRNAs to the 39 UTRs of target genes stimulates
rapid degradation of the target transcript [58]. Therefore, future
studies are required to investigate if different miRNA-mediated
specificities may also apply for the regulation of MCPH1 isoforms.
In summary, our results provide new insights into expression
pattern of human MCPH1 gene contributing to better under-
standing of different functions attributed to the gene product.
Materials and Methods
Cell culture
Adherent cell lines were grown in a monolayer in minimum
essential medium (MEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS) and maintained
at 37uC in 5% CO2. The 562T cell line is derived from patient
fibroblasts and contains the homozygous nonsense mutation
c.427dupA (p.N143fsX147) in MCPH1 [18]. HeLa cells were
obtained from DSMZ (Braunschweig, DE). COS-7 and 293T cells
were obtained from ATCC (Manassas, VA, USA).
Cell synchronization
A double thymidine block was used for HeLa cell synchroni-
zation. Cells were first incubated with 2 mM thymidine for 18 h.
After the first thymidine block, cells were incubated in normal
culture medium for 9 h, and thymidine (2 mM) was then added
for a further 17 h. This procedure synchronized cells at the G1/S
border. Cell cycle arrest was subsequently released by growing
cells in thymidine-free medium. After release, cells were harvested
in 1-h intervals for 12 h. The synchrony of HeLa cells was
monitored using flow cytometry of DAPI-stained cells.
Molecular cloning of MCPH1 coding sequence
Full-length and alternatively spliced sequences of human
MCPH1 were isolated from HeLa cells with specific PCR primers
and Phusion polymerase (Finnzyme, Espoo, FI). PCR products
were cloned in-frame with the EGFP cDNA being a 59tag for the
MCPH1 into lentiviral vector pCL1THPC.EGIN, thereby creat-
ing the vector pCL1THPC.EGMCPH1IN. The neomycin resis-
tance gene (ncpt II) was co-expressed with the fusion protein via an
EMCV IRES sequence. The vector also contained the tetO
sequence in the 39LTR which upon proviral integration of the
vector into the target cell genome was copied also to the 59LTR
and therefore allowed better regulation of the protein expression
via doxycyclin. Constructs were verified by sequencing.. The
sequence of human MCPH1 is available in the Ensembl data base
under accession number ENSG00000147316. Detailed cloning
strategies, vector maps and primer sequences are available upon
request.
Lentiviral transduction and complementation of MCPH1-
deficient cells
HEK 293T cells were transfected using FuGene HD (Roche)
with 6 mg of an HIV1 helper plasmid pCD/NL-BH, kindly
obtained from Jakob Reiser, New Orleans, expression construct
for HIV1 gag/pol/rev (pCD/NL-BH) [59], 6 mg of the envelope
vector (pczVSV-G) [60], and 6 mg of the vector plasmids
pCL1THPC.EGMCPH1IN (doxycycline-dependent transgene
with EGFP tag and IRES-NeoR cassette) or puc2CL1tTRKRA-
BIH (KRAB-based tet repressor with IRES-HygroR cassette),
respectively. Viral supernatants were harvested 48 h after trans-
fection, filtered through a 0.45-mm filter (Sartorius AG, Germany)
and used to co-transduce 562T fibroblasts and HeLa cells. The
selection of cells with integrated copies of the tTR-KRAB-
expressing vector was accomplished using hygromycin B (200 mg/
ml) selection at 24–48 h following transduction. After successful
selection, doxycycline (1 ng/ml) was added to induce the
expression of GFP or GFP-MCPH1 and the Neo resistance gene.
Selection with G418 (350–400 mg/ml) was started 48 h after
incubation with doxycycline and continued until the nontrans-
duced cells had died. Complementation of defective chromosome
condensation in transduced MCPH1-deficient fibroblasts was
verified using chromosome analysis. Chromosome preparation
was performed using standard methods, and .1000 nuclei per
preparation were scored. The percentage of prophase-like cells
was determined counting nuclei with condensed chromosomes
and an intact nucleus. Mitotic index was determined counting the
metaphase spreads as described previously [14].
Antibodies
Rabbit antiserum (ab2612) and goat antiserum (AF3998) to
MCPH1 were obtained from Abcam (Cambridge, UK) and R&D
Systems (Minneapolis, MN, USA), respectively. The rabbit
polyclonal antiserum against MCPH1 (fig. 5) was kindly furnished
by Dr. Tatsuya Hirano (RIKEN, JP). Antibodies against GFP
(ab13970), pericentrin (ab4448), c-tubulin (ab11316), c-H2AX
(pS139, ab11174), nuclear matrix protein p84 (ab487), and
GAPDH (ab9385) were obtained from Abcam. Mouse anti-
histone H3 (pS10, #9706) was obtained from Cell Signaling
(Danvers, MA, USA); A rabbit anti-c-tubulin antibody (T5192)
was obtained from Sigma (St. Louis, MO, USA). Alexa Fluor-
labeled secondary antibodies were obtained from Invitrogen.
Analysis of MCPH1 Isoforms
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e40387
HRP-conjugated secondary antibodies were from GE Healthcare
(Little Chalfont, UK).
Site-specific mutagenesis by overlap extension
To delete several NLSs in the wild-type (wt) MCPH1 we
performed mutagenesis by overlap extension, as previously
described [61]. The cloned coding region of full-length MCPH1
in the S11IN vector was used as the template. In the first step, two
fragments of the gene sequence were amplified in two separate
PCRs. Each reaction used one flanking primer that hybridizes at
one end of the target sequence and one internal primer that
hybridizes to the site of the mutation with the desired deletion.
Following PCR, the wt sequence was removed by cleavage with
DpnI. Because the two internal primers used in the first PCR
overlapped, the two generated fragments could be fused in a
subsequent primer-extension reaction. The obtained sequences
were digested with BsrGI and subcloned into the mammalian
expression vector pEGFP-N3 (Clontech, Mountain View, CA,
USA), which allows for in-frame fusion with enhanced GFP
expression. The orientation and correctness of the constructs were
verified by sequencing. Primer sequences are available on request.
Cell transfection and subcellular localization
For subcellular detection of the GFP-tagged proteins, HeLa or
COS-7 cells were cultured in 6-well plates in 3 ml MEM medium
containing 10% FBS and transfected with 1 mg of the respective
plasmid using 3 ml GeneJuiceH Transfection Reagent (Novagen/
Merck, Darmstadt, DE) according to the manufacturer’s instruc-
tions. After 48 h, cells were harvested and analysed using cell
fractionation or immunofluorescence.
RNA interference
siRNA-mediated depletion of MCPH1 was performed as
previously described [18].
Whole-cell extracts and cell fractionation
For the preparation of whole-cell extracts, cell pellets were
washed in cold PBS and resuspended in lysis buffer (50 mM Tris,
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF,
0.1 mM NaVO2, 25 mM ß-glycerophosphate, 0.2% (v/v) TritonH
X-100, 0.3% (w/v) Nonidet P-40, and protease inhibitor cocktail
(Roche Diagnostics, Mannheim, DE)). Cells were lysed on ice for
45 min. The separation of nuclear extracts from cytoplasmic
fractions was performed using a Nuclear/Cytosol Extraction Kit
(BioVision, Mountain View, CA, USA). Aliquots of equal amounts
of protein were mixed with NuPAGEH sample buffer (Invitrogen),
heated at 70uC for 10 min, and electrophoresed for western
transfer using the NuPAGEH system (Invitrogen), according to the
manufacturer’s instructions. Membranes were blocked, incubated
with the indicated antibodies, and developed using enhanced
chemiluminescence.
Immunofluorescence
For immunofluorescence, cells grown on glass coverslips were
fixed either in 220uC methanol/acetone (1:1) for 7 min to
preserve centrosomes or, in other experiments, with 4% parafor-
maldehyde in PBS (pH 7.4) for 15 min at room temperature and
permeabilized with ice-cold methanol for 30 min on ice. Cells
were incubated with PBS containing 20% FBS as a blocking agent
for 30 min and then with the indicated antibodies for approx-
imately 1 h at room temperature. After being washed three times
with PBS, cells were incubated with the respective secondary
antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594 for
30 min. DNA was stained with 1 mg/ml DAPI for 5 min.
Following a PBS rinse, coverslips were mounted with ProLong
antifade reagent (Invitrogen). Fluorescence images were captured
and processed using the inverse microscope Axiovert 200 M
equipped with the Plan Apo 636/1.4 oil immersion objective and
AxioVision software (Carl Zeiss, Jena, DE).
Real-time PCR
Total RNA was isolated using an RNeasy mini kit (Qiagen,
Hilden, DE). DNA contamination was removed by treating the
RNA samples with the Turbo DNA-freeTM Kit (Ambion, Austin,
TX, USA). First-strand synthesis was performed using a Tran-
scriptor First Strand cDNA Synthesis Kit (Roche). A total of 1 ml
of each first-strand sample was used for real-time PCR, which was
performed using PerfeCTaTM SYBRH Green SuperMix (Quanta
BioSciences, Gaithersburg, MD, USA) and the iQ Real-Time
PCR System (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s recommendations. A total of 48 cycles were
performed (each cycle consisted of 15 s at 95uC, 30 s at 60uC
and 30 s at 72uC). UBC-, B2M-, HPRT-, and GAPDH-specific
primers (PrimerDesign, Southampton, UK) were used as endog-
enous references. All samples were analyzed in duplicate. A
dilution series of eachMCPH1 variant cloned in a particular vector
was used for the creation of copy number standard curves. Human
Multiple Tissue cDNA panels I, II and fetal (Clontech) were used
for the comparison of the expression of MCPH1 isoforms in
different tissues. Primer sequences were as follows: FL-fw 59-
ttatagttgactgtaacatggagacg-39; FL-rev 59-atgaggtttgatgaggtccttaa-
39; De8-fw 59-gtgatactttgtgttcaggtgtt-39; De8-rev: 59-
tttgcctctcccacttttctt-39; De9–14-fw 59-acttgctgtcttgtggaacttcta-39
and De9–14-rev: 59-acttcactcccctcagttattcatact-39.
59 RACE assay
59 RACE was performed using a FirstChoiceH RLM-RACE kit
(Ambion) according to the manufacturer’s instructions.
Supporting Information
Figure S1 MCPH1 do not colocalize with centrosomes.
Non-transduced (NT) fibroblasts or fibroblasts with ectopic
expression of GFP or of GFP fusions with full length (FL) MCPH1
or with the indicated isoforms were methanol fixed and stained
with c-tubulin-specific antibody (red) to visualize the centrosomes.
MCPH1 isoforms were detected via its GFP tag (green). Squares
frame areas for a detailed view displayed in the upper right corner.
Please note the clear nuclear localization of MCPH isoforms. Scale
bar = 5 mm.
(TIF)
Figure S2 FLAG-tagged MCPH1 do not colocalize with
centrosomes. Non-transduced (NT) HeLa cells or HeLa cells
transiently expressing FLAG or FLAG-tagged full length (FL)
MCPH1 or the indicated isoforms were methanol fixed and
stained with a c-tubulin-specific antibody (red) to visualize
centrosomes. MCPH1 isoforms were detected via its FLAG-tag
(green), nuclei were visualized by DAPI staining (blue). Merging
the signals depicts the missing colocalization of MCPH1 with
centrosomes (lower panel), a detailed view of the centrosomes is
shown in the upper right corner. Scale bar = 10 mm.
(TIF)
Table S1 Computed scores representing predicted
strengths of function of the canonical splice donors in
human MCPH1.
(DOCX)
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Table S2 Expression of MCPH1 splicing variants in
human adult and fetal tissues.
(DOCX)
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